glp 1 receptor agonists Potential Use of GLP-1 and GIP/GLP-1 for Respiratory Disorders: Where Are We at? Frontiers | GLP-1 receptor agonist

K., Kochanek, S

Among the several obesity therapies, phentermine, semaglutide, and tirzepatide exhibited the greatest prescription rates, with approximately 0.74 million, 0.42 million, and 0.25 million monthly prescriptions, respectively, as of February 2024

In this system, the quality of systematic reviews included RCTs set to be high and downgraded by 5 criteria assessment: (1) risk of bias in individual studies, (2) inconsistency of results between studies, (3) indirectness of evidence, (4) imprecision, and (5) publication bias

Novel diabetes drugs and the cardiovascular specialist

A recent nested case-control study based on a French national health insurance system database reported a significant association between thyroid cancer and GLP1 receptor agonist use (hazard ratio 1.46, 95% confidence interval 1.23 to 1.74).7 However, the comparator in that study was non-use of GLP1 receptor agonists, rather than an active comparator